Marks Wealth’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-236,668
Closed -$28.9M 20
2025
Q4
$28.9M Buy
+236,668
New +$27.1M 9.66% 6

Other funds holding XBI

Marks Wealth's XBI Position: Q1 2026 in Review

Marks Wealth sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 236,668 shares — an estimated $28.9M sold.

Marks Wealth first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $28.9M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Marks Wealth reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
  • Marks Wealth sold 236,668 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $28.9M.
  • Marks Wealth first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
  • Marks Wealth's State Street SPDR S&P Biotech ETF position peaked at $28.9M in Q4 2025.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Marks Wealth's 13F filing for Q1 2026, filed 4 May 2026.